Whitney Finley, NP
Family · Anderson, INNPI 1578209961
Payments from drug & device makers
Across 366 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$894
- Bayer$877
- Lilly USA, LLC$663
- Axsome Therapeutics, Inc.$659
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,793100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $1,054 |
| AbbVie | 62 | $1,024 |
| AstraZeneca | 15 | $894 |
| Bayer | 54 | $877 |
| Lilly USA, LLC | 30 | $663 |
| Axsome Therapeutics, Inc. | 17 | $659 |
| Boehringer Ingelheim | 18 | $328 |
| Dexcom, Inc. | 15 | $294 |
| Amgen | 19 | $243 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $234 |
| Idorsia Pharmaceuticals US Inc | 9 | $206 |
| Exact Sciences | 11 | $195 |
| Pfizer | 10 | $153 |
| Mylan Specialty L.p. | 1 | $122 |
| Astellas Pharma US Inc | 4 | $108 |
| Verona Pharma, Inc. | 4 | $96 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| GSK | 4 | $67 |
| Shield Therapeutics Inc | 1 | $51 |
| Boston Scientific | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Edwards Lifesciences | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 5 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $39 |
| Johnson & Johnson | 2 | $37 |
| Merck | 2 | $30 |
| Grifols USA, LLC | 1 | $27 |
| Organon | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Medtronic | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,793 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $27,558 |
| RexultiBrexpiprazole | 11 | $22,158 |
| MounjaroTirzepatide | 18 | $18,914 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $17,474 |
| FarxigaDapagliflozin Propanediol | 11 | $13,867 |
| JardianceEmpagliflozin | 20 | $13,071 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,817 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 94 | $1,574 |
| Gabapentin | 71 | $1,075 |
| Bupropion XlBupropion Hcl | 45 | $1,057 |
| Omeprazole | 76 | $1,043 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,043 |
| Pregabalin | 18 | $963 |
| Duloxetine Hcl | 30 | $762 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,054 | $27,55825 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $94 | $22,15811 claims |
| Lilly USA, LLCMounjaro | $663 | $18,91418 claims |
| GSKBreo Ellipta | $67 | $17,47439 claims |
| AstraZenecaFarxiga | $894 | $13,86711 claims |
| Boehringer IngelheimJardiance | $328 | $13,07120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Anderson
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.